Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% below fair value
$0.35−0.01 (-2.51%)
Close on Nov 16, 2026Market cap $37.82MP/E –Yield –
Caribou Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Caribou Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -1090.9%. For fiscal 2025 it was -1329.4%, against -1667.2% the year before. The highest annual figure on record is -292.2% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1329.4% | +337.8 |
| FY2024 | Dec 31, 2024 | -1667.2% | −1330.5 |
| FY2023 | Dec 31, 2023 | -336.6% | +431.5 |
| FY2022 | Dec 31, 2022 | -768.2% | −70.3 |
| FY2021 | Dec 31, 2021 | -697.8% | −405.6 |
| FY2020 | Dec 31, 2020 | -292.2% | +300.5 |
| FY2019 | Dec 31, 2019 | -592.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1690.4% | +93.6 |
| Q1 FY2026 | Mar 31, 2026 | -1096.4% | +727.4 |
| Q4 FY2025 | Dec 31, 2025 | -722.0% | +1149.7 |
| Q3 FY2025 | Sep 30, 2025 | -1337.6% | +551.6 |
| Q2 FY2025 | Jun 30, 2025 | -1784.0% | −528.1 |
| Q1 FY2025 | Mar 31, 2025 | -1823.8% | +70.1 |
| Q4 FY2024 | Dec 31, 2024 | -1871.7% | −819.4 |
| Q3 FY2024 | Sep 30, 2024 | -1889.2% | −1827.4 |
| Q2 FY2024 | Jun 30, 2024 | -1255.8% | −380.5 |
| Q1 FY2024 | Mar 31, 2024 | -1893.9% | −1005.3 |
| Q4 FY2023 | Dec 31, 2023 | -1052.3% | −224.1 |
| Q3 FY2023 | Sep 30, 2023 | -61.8% | +741.6 |
| Q2 FY2023 | Jun 30, 2023 | -875.3% | −197.1 |
| Q1 FY2023 | Mar 31, 2023 | -888.5% | −105.8 |
| Q4 FY2022 | Dec 31, 2022 | -828.2% | −30.8 |
| Q3 FY2022 | Sep 30, 2022 | -803.4% | −335.3 |
| Q2 FY2022 | Jun 30, 2022 | -678.2% | +403.4 |
| Q1 FY2022 | Mar 31, 2022 | -782.8% | +47.9 |
| Q4 FY2021 | Dec 31, 2021 | -797.4% | +748.5 |
| Q3 FY2021 | Sep 30, 2021 | -468.1% | +218.8 |
| Q2 FY2021 | Jun 30, 2021 | -1081.6% | −1055.0 |
| Q1 FY2021 | Mar 31, 2021 | -830.7% | −217.6 |
| Q4 FY2020 | Dec 31, 2020 | -1545.8% | – |
| Q3 FY2020 | Sep 30, 2020 | -686.9% | – |
| Q2 FY2020 | Jun 30, 2020 | -26.6% | – |
| Q1 FY2020 | Mar 31, 2020 | -613.1% | – |
See a number that looks wrong?